Home

Eli Lilly (LLY)

775.10
-0.35 (-0.05%)
NYSE · Last Trade: Jun 30th, 8:36 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close775.45
Open778.54
Bid774.55
Ask775.39
Day's Range774.64 - 785.00
52 Week Range677.09 - 972.53
Volume195,662
Market Cap741.44B
PE Ratio (TTM)63.07
EPS (TTM)12.3
Dividend & Yield6.000 (0.77%)
1 Month Average Volume3,076,393

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?investors.com
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
$1,000 Invested in VUG Could Turn Into $50,000fool.com
Via The Motley Fool · June 29, 2025
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via MarketBeat · June 29, 2025
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)fool.com
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.
Via The Motley Fool · June 29, 2025
Which Stock Will Dominate the Weight Management Market Through 2030?fool.com
Via The Motley Fool · June 28, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · June 27, 2025
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugsbenzinga.com
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.
Via Benzinga · June 27, 2025
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launchstocktwits.com
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry.
Via Stocktwits · June 26, 2025
5 Biotech Stocks with Highly Anticipated Pending Resultsstocktwits.com
Via Stocktwits · June 26, 2025
Why This Weight Loss Drug Company's Stock Surged Todayfool.com
Via The Motley Fool · June 26, 2025
3 Growth Stocks I'm Loading Up Onfool.com
Via The Motley Fool · June 26, 2025
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring late-stage assets, weighed on profitability. CEO Dave Ricks noted that the company is facing “a lot of investor focus right now on tariffs and trade,” while CFO Lucas Montarce cited a “26% increase in marketing, selling and administrative expenses” as Lilly ramped up promotion for new launches.
Via StockStory · June 26, 2025
Why Shares in Novo Nordisk Lost Weight Todayfool.com
Via The Motley Fool · June 25, 2025
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Showsbenzinga.com
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.
Via Benzinga · June 25, 2025
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesityinvestors.com
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via Investor's Business Daily · June 25, 2025
What's Going On With Viking Therapeutics Stock On Wednesday?benzinga.com
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via Benzinga · June 25, 2025
Tesla's Robotaxi Rolloutfool.com
Via The Motley Fool · June 25, 2025
Which S&P500 stocks are moving on Wednesday?chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · June 25, 2025
7 Space Stocks I'd Buy Without Hesitationfool.com
Via The Motley Fool · June 25, 2025
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrowfool.com
Via The Motley Fool · June 25, 2025
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s Soldstocktwits.com
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed.
Via Stocktwits · June 25, 2025
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lillybenzinga.com
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio.
Via Benzinga · June 24, 2025
New AI Rollouts Signal Shift From Hype to Healthcare Reality
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END
Via FinancialNewsMedia · June 24, 2025
Why Novo Nordisk Stock Is Sinking Todayfool.com
Via The Motley Fool · June 23, 2025
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’stocktwits.com
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically best for patients.
Via Stocktwits · June 23, 2025